Pharvaris (PHVS) Cash from Operations (2020 - 2026)
Pharvaris' (PHVS) quarterly Cash from Operations came in at 57092530.86 in Q1 2026, down 41.08% YoY from 96901332.11 in Q1 2025, and down 29.23% on a QoQ basis from 44178661.81 in Q4 2025.
Pharvaris (PHVS) Cash from Operations (2020 - 2026) Analysis & Trends
Pharvaris (PHVS) has 7 years of Cash from Operations data on file, last reported at 57092530.86 in Q1 2026.
- Quarterly Cash from Operations fell 41.08% year-over-year to 57092530.86 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 171061398.25 (down 18.66% YoY) and the FY2025 annual result came in at 154867325.53, down 19.11% from the prior year.
- Cash from Operations declined to 57092530.86 in Q1 2026, from 44178661.81 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 49734863933114.66 in Q3 2023 to a low of 49750167596353.37 in Q2 2023.
- A 5-year average of 927569736.49 and a median of 29811657.54 in 2024 frame the typical range for Cash from Operations.
- The widest YoY moves for Cash from Operations: up 324922255.76% in 2023, down 340632884.32% in 2023.
- Tracing PHVS's Cash from Operations over 5 years: stood at 20826281.92 in 2022, then fell by 23.0% to 25616942.47 in 2023, then slumped by 45.81% to 37351343.8 in 2024, then fell by 18.28% to 44178661.81 in 2025, then fell by 29.23% to 57092530.86 in 2026.
- The last three Cash from Operations figures came in at 57092530.86 (Q1 2026), 44178661.81 (Q4 2025), and 35853648.89 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Pharvaris | 2.29 Bn | 1.92 Bn | - | -43.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.94 Mn |
| Jun 30, 2026 | -43.94 Mn |
| Mar 31, 2026 | -57.09 Mn |
| Mar 31, 2026 | -57.09 Mn |
| Dec 31, 2025 | -44.18 Mn |
| Dec 31, 2025 | -44.18 Mn |
| Sep 30, 2025 | -35.85 Mn |
| Sep 30, 2025 | -35.85 Mn |
| Jun 30, 2025 | -33.94 Mn |
| Jun 30, 2025 | -33.94 Mn |
| Mar 31, 2025 | -40.47 Mn |
| Mar 31, 2025 | -40.47 Mn |
| Dec 31, 2024 | -37.35 Mn |
| Dec 31, 2024 | -37.35 Mn |
| Sep 30, 2024 | -36.53 Mn |
| Sep 30, 2024 | -36.53 Mn |
| Jun 30, 2024 | -29.81 Mn |
| Jun 30, 2024 | -29.81 Mn |
| Mar 31, 2024 | -26.32 Mn |
| Mar 31, 2024 | -26.32 Mn |